FDA reviewing safety of Botox

WASHINGTON (Reuters) - Regulators said on Friday they were reviewing the safety of Allergan Inc's (AGN.N: Quote, Profile, Research) Botox and a competing product after reports of deaths and serious reactions in some patients. The Food and Drug Administration said the most serious cases included hospitalizations and deaths and occurred mostly in children treated for cerebral palsy-associated limb spasticity, a use not approved in the United States.